List of Osmolex Er drug patents

Osmolex Er is owned by Adamas Pharma.

Osmolex Er contains Amantadine Hydrochloride.

Osmolex Er has a total of 18 drug patents out of which 0 drug patents have expired.

Osmolex Er was authorised for market use on 16 February, 2018.

Osmolex Er is available in tablet, extended release;oral dosage forms.

Osmolex Er can be used as treatment of drug-induced extrapyramidal reactions in adult patients with parkinson's disease; treatment of parkinson's disease, treatment of drug-induced extrapyramidal reaction in adult patients, a process for treating a patient suffering from parkinson's syndrome and in need of treatment, treatment of parkinson's disease; treatment of drug-induced extrapyramidal reactions in adult patients with parkinson's disease; treatment of drug-induced extrapyramidal reaction in adult patients, treatment of parkinson's disease; treatment of drug-induced extrapyramidal reactions in adult patients with parkinson's disease.

The generics of Osmolex Er are possible to be released after 15 February, 2038.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895617 ADAMAS PHARMA Composition and method for treating neurological disease
Nov, 2025

(2 years from now)

US8895618 ADAMAS PHARMA Composition and method for treating neurological disease
Nov, 2025

(2 years from now)

US8796337 ADAMAS PHARMA Composition and method for treating neurological disease
Nov, 2025

(2 years from now)

US8895614 ADAMAS PHARMA Composition and method for treating neurological disease
Nov, 2025

(2 years from now)

US8987333 ADAMAS PHARMA Composition and method for treating neurological disease
Nov, 2025

(2 years from now)

US8889740 ADAMAS PHARMA Composition and method for treating neurological disease
Nov, 2025

(2 years from now)

US9072697 ADAMAS PHARMA Composition and method for treating neurological disease
Nov, 2025

(2 years from now)

US8895616 ADAMAS PHARMA Composition and method for treating neurological disease
Nov, 2025

(2 years from now)

US8895615 ADAMAS PHARMA Composition and method for treating neurological disease
Nov, 2025

(2 years from now)

US8574626 ADAMAS PHARMA Osmotic device containing amantadine and an osmotic salt
Nov, 2025

(2 years from now)

US8389578 ADAMAS PHARMA Composition and method for treating neurological disease
Jan, 2028

(4 years from now)

US8252331 ADAMAS PHARMA Osmotic device containing amantadine and an osmotic salt
Mar, 2030

(7 years from now)

US10512617 ADAMAS PHARMA Composition and method for treating neurological disease
Feb, 2038

(15 years from now)

US10213393 ADAMAS PHARMA Composition and method for treating neurological disease
Feb, 2038

(15 years from now)

US10500172 ADAMAS PHARMA Composition and method for treating neurological disease
Feb, 2038

(15 years from now)

US10500171 ADAMAS PHARMA Composition and method for treating neurological disease
Feb, 2038

(15 years from now)

US10213394 ADAMAS PHARMA Composition and method for treating neurological disease
Feb, 2038

(15 years from now)

US10500170 ADAMAS PHARMA Composition and method for treating neurological disease
Feb, 2038

(15 years from now)

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 February, 2018

Treatment: Treatment of parkinson's disease; Treatment of drug-induced extrapyramidal reactions in adult patients with parkinson's disease; Treatment of drug-induced extrapyramidal reaction in adult patients; A process for treating a patient suffering from parkinson's syndrome and in need of treatment

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in